Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease

Figure 4 Differentially abundant metabolic pathways between metabolic-dysfunction associated steatotic liver disease and ornithine aspartate by Lefse analysis. Statistical confidence was assessed using the Kruskal-Wallis test. Metabolic pathways were ranked by linear discriminant analysis (LDA) score. Differences were considered significant for a logarithmic LDA score threshold of ± 4.0 and P-value < 0.05. MASLD: Metabolic-dysfunction associated steatotic liver disease; LOLA: Ornithine aspartate.